chr17-43099787-A-G

Variant summary

Our verdict is Uncertain significance. Variant got 3 ACMG points: 3P and 0B. PM5PP3

The NM_007294.4(BRCA1):ā€‹c.535T>Cā€‹(p.Tyr179His) variant causes a missense change. The variant allele was found at a frequency of 0.00000746 in 1,608,308 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā˜…ā˜…). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. Y179C) has been classified as Benign.

Frequency

Genomes: š‘“ 0.0000066 ( 0 hom., cov: 31)
Exomes š‘“: 0.0000076 ( 0 hom. )

Consequence

BRCA1
NM_007294.4 missense

Scores

7
8
4

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:9B:1

Conservation

PhyloP100: 3.92
Variant links:
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 3 ACMG points.

PM5
Other missense variant is known to change same aminoacid residue: Variant chr17-43099786-T-C is described in Lovd as [Pathogenic].
PP3
MetaRNN computational evidence supports a deleterious effect, 0.813

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE Protein UniProt
BRCA1NM_007294.4 linkuse as main transcriptc.535T>C p.Tyr179His missense_variant 7/23 ENST00000357654.9 NP_009225.1 P38398-1

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Protein Appris UniProt
BRCA1ENST00000357654.9 linkuse as main transcriptc.535T>C p.Tyr179His missense_variant 7/231 NM_007294.4 ENSP00000350283.3 P38398-1

Frequencies

GnomAD3 genomes
AF:
0.00000657
AC:
1
AN:
152204
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000147
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.00000795
AC:
2
AN:
251454
Hom.:
0
AF XY:
0.0000147
AC XY:
2
AN XY:
135896
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000176
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000755
AC:
11
AN:
1456104
Hom.:
0
Cov.:
30
AF XY:
0.00000828
AC XY:
6
AN XY:
724798
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.00
Gnomad4 ASJ exome
AF:
0.00
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000994
Gnomad4 OTH exome
AF:
0.00
GnomAD4 genome
AF:
0.00000657
AC:
1
AN:
152204
Hom.:
0
Cov.:
31
AF XY:
0.00
AC XY:
0
AN XY:
74350
show subpopulations
Gnomad4 AFR
AF:
0.00
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.0000147
Gnomad4 OTH
AF:
0.00
ExAC
AF:
0.00000824
AC:
1
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:9Benign:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Hereditary cancer-predisposing syndrome Uncertain:3
Uncertain significance, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthAug 02, 2023This missense variant replaces tyrosine with histidine at codon 179 of the BRCA1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in a breast cancer case-control meta-analysis in 1/53461 unaffected individuals and absent in 60466 cases (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_006563) and among individuals who underwent BRCA1 mutation screening (PMID: 16267036). This variant also has been reported to have a tumor pathology likelihood ratio for pathogenicity of 0.2938 (PMID: 31131967). This variant has been identified in 2/251454 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsNov 17, 2023The p.Y179H variant (also known as c.535T>C), located in coding exon 6 of the BRCA1 gene, results from a T to C substitution at nucleotide position 535. The tyrosine at codon 179 is replaced by histidine, an amino acid with similar properties. This alteration has been identified in multiple individuals diagnosed with breast cancer (Rizzolo P et al. Int J Cancer, 2019 Jul;145:390-400; Boga I et al. Eur J Breast Health, 2023 Jul;19:235-252). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Uncertain significance, criteria provided, single submittercurationSema4, Sema4Mar 11, 2022- -
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitterclinical testingAll of Us Research Program, National Institutes of HealthNov 30, 2023This missense variant replaces tyrosine with histidine at codon 179 of the BRCA1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in a breast cancer case-control meta-analysis in 1/53461 unaffected individuals and absent in 60466 cases (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_006563) and among individuals who underwent BRCA1 mutation screening (PMID: 16267036). This variant also has been reported to have a tumor pathology likelihood ratio for pathogenicity of 0.2938 (PMID: 31131967). This variant has been identified in 2/251454 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Benign, no assertion criteria providedclinical testingDepartment of Medical and Surgical Sciences, University of BolognaSep 01, 2023BP1(Strong)+BP5(Strong) according to ACMG/AMP classification guidelines specified for BRCA1 & BRCA2 (Classification Criteria V1.0.0 2023-09-08 - https://cspec.genome.network/cspec/ui/svi/affiliation/50087) (PMID: 38160042) -
Uncertain significance, criteria provided, single submitterclinical testingBaylor GeneticsJan 17, 2024- -
not provided Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoApr 09, 2024The BRCA1 c.535T>C (p.Tyr179His) variant has been reported in the published literature in an individual with male breast cancer (PMID: 30613976 (2019)). It has also been identified in a reportedly healthy individual (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/BRCA1)). This variant has also been characterized as a likely benign variant in a multifactorial likelihood study (PMID: 31131967 (2019)). The frequency of this variant in the general population, 0.000008 (2/251454 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is benign or damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxAug 08, 2023Observed in an individual undergoing BRCA1/2 testing and in a male with breast cancer (Judkins et al., 2005; Rizzolo et al., 2019); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Not observed at significant frequency in large population cohorts (gnomAD); Also known as 654T>C; This variant is associated with the following publications: (PMID: 26295337, 29884841, 32377563, 20215511, 9788437, 30613976, 31853058, 16267036, 31131967) -
Malignant tumor of breast Uncertain:1
Uncertain significance, no assertion criteria providedclinical testingDepartment of Pathology and Laboratory Medicine, Sinai Health System-The BRCA1 p.Tyr179His variant was not identified in the literature, nor was it identified in the HGMD, UMD, COSMIC, BIC or LOVD databases. The UMD database identified another variant at this amino acid position (p.Tyr179Cys (c.536A>G)) that was observed in 4 (of 29) individuals as co-occurring with a second pathogenic variant in BRCA1 or BRCA2, increasing the likelihood that an alteration to this residue may not have clinical significance. The p.Tyr179 residue is conserved in mammals but not in all lower organisms and computational analyses (PolyPhen-2, SIFT, AlignGVGD) suggest that the p.Tyr179His variant may impact the protein; however, this information is not very predictive of pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined at this time. This variant is classified as a variant of unknown significance. -
Hereditary breast ovarian cancer syndrome Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingLabcorp Genetics (formerly Invitae), LabcorpDec 18, 2023This sequence change replaces tyrosine, which is neutral and polar, with histidine, which is basic and polar, at codon 179 of the BRCA1 protein (p.Tyr179His). This variant is present in population databases (rs587781761, gnomAD 0.002%). This missense change has been observed in individual(s) with a high risk for breast and ovarian cancer and/or breast cancer (PMID: 16267036, 30613976). ClinVar contains an entry for this variant (Variation ID: 141458). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BRCA1 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.40
BayesDel_addAF
Pathogenic
0.49
D
BayesDel_noAF
Pathogenic
0.48
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Benign
0.31
.;T;.;.;.;.;.;T;.;T;.;T;T;.;T;T
Eigen
Uncertain
0.56
Eigen_PC
Uncertain
0.51
FATHMM_MKL
Uncertain
0.90
D
LIST_S2
Uncertain
0.96
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Pathogenic
0.84
D
MetaRNN
Pathogenic
0.81
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
1.1
D
MutationAssessor
Uncertain
2.5
M;M;M;M;.;M;.;.;.;.;.;.;.;.;.;.
PrimateAI
Uncertain
0.66
T
PROVEAN
Benign
-0.42
N;N;N;N;N;N;N;N;N;N;N;.;N;N;N;D
REVEL
Pathogenic
0.66
Sift
Pathogenic
0.0
D;D;D;D;D;D;D;D;D;D;D;.;D;D;D;D
Sift4G
Benign
0.43
T;T;T;T;T;T;.;.;T;.;T;.;D;.;D;.
Polyphen
1.0, 1.0, 1.0
.;D;.;.;.;D;.;D;.;.;D;.;.;.;.;.
Vest4
0.62
MutPred
0.37
Gain of disorder (P = 0.0485);Gain of disorder (P = 0.0485);Gain of disorder (P = 0.0485);Gain of disorder (P = 0.0485);.;Gain of disorder (P = 0.0485);.;.;.;.;Gain of disorder (P = 0.0485);Gain of disorder (P = 0.0485);Gain of disorder (P = 0.0485);.;Gain of disorder (P = 0.0485);.;
MVP
0.93
MPC
0.47
ClinPred
0.86
D
GERP RS
5.2
Varity_R
0.28
gMVP
0.30

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs587781761; hg19: chr17-41251804; COSMIC: COSV58801993; COSMIC: COSV58801993; API